The Epidemiology of the Revision Total Hip Arthroplasty in the United States From 2016 to 2022

• Published in: Arthroplasty today 2024-12, Vol.30, p.101517, Article 101517
• Main Authors: Bains, Sandeep S., Dubin, Jeremy A., Salib, Christopher G., Monárrez, Rubén, Remily, Ethan, Hameed, Daniel, Swartz, Gabrielle N., Katanbaf, Reza, Nace, James, Delanois, Ronald E.
• Format: Article
• Language: English
• Subjects: Dislocation; Epidemiology; Infection; Original Research; Revision; Total hip arthroplasty
• ISSN: 2352-3441; 2352-3441
• DOI: 10.1016/j.artd.2024.101517

The number of revision total hip arthroplasties (THAs) is projected to reach 572,000 cases annually by 2030 in the United States. This may be attributed to the successes of primary THAs combined with an aging population, patients desire to remain active, and expanded indications for younger patients. Given the evolving nature of revision THAs, an epidemiological analysis of (1) etiologies; (2) demographics, including age and region; and (3) lengths of stay (LOSs) may minimize the gap between appropriate understanding and effective intervention. From 2016 to 2022, a national, all-payer database was queried. Incidences and indications were analyzed for a total of 102,476 patients who had revision THA procedures. Patients were stratified according to etiology of failure, age, US census region, primary payor class, and mean LOS. The most common etiologies for revision THA procedures were dislocation (16.7%) and infection (12.7%), followed by periprosthetic fracture (6.9%). The largest age group was 65-74 years (30.9%), followed by >75 years (28.6%), then 55-64 (26.5%). The South had the largest total procedure cohort (36.9%), followed by the Midwest (27.5%), then the Northeast (19.7%), and the West (15.9%). The mean LOS was 4.10 days (range, 1.0-20.0). Dislocation and infection remain leading indications for revision THA. These findings can properly guide surgeons toward appropriate management as well as toward active steps to minimizing these outcomes.